02.05.2024 - KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and ADÂ with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of .
02.11.2023 - First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; dosing of first patient in Phase 2 AD trial expected in the fourth quarter of 2023 ASH abstract to be .
28.08.2023 - WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today .